<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04988048</url>
  </required_header>
  <id_info>
    <org_study_id>0001/2021</org_study_id>
    <nct_id>NCT04988048</nct_id>
  </id_info>
  <brief_title>Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina</brief_title>
  <acronym>ECEHeVac</acronym>
  <official_title>Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Public Health, Argentina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Russian Direct Investment Fund</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ministry of Public Health, Argentina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, open, multicenter, collaborative and adaptive non-inferiority trial to evaluate&#xD;
      the immunogenicity and reactogenicity of the heterologous vaccination schedules made up of&#xD;
      the combination of vaccines available in Argentina (Sputnik-V, AstraZeneca, Sinopharm and&#xD;
      Moderna); and to compare the immunogenicity and reactogenicity of heterologous and homologous&#xD;
      vaccination schedules.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      More than a hundred COVID-19 vaccines based on different technologies are currentlyin the&#xD;
      clinical phase of development around the world. More than a dozen derived from different&#xD;
      platforms have been approved by regulatory entities in several countries and are used to&#xD;
      immunize the world's population.&#xD;
&#xD;
      The dynamics of the COVID-19 pandemic, the emergence of variants, the magnitude and&#xD;
      durability of the immune response, the effectiveness of approved vaccination schemes, as well&#xD;
      as the possibility of combining vaccines from various platforms, are some of the issues to be&#xD;
      facedin public health decision-making, in order to deliver the best protection standards to&#xD;
      the population.&#xD;
&#xD;
      Given the dynamics of the disease in Argentina, the access to different COVID-19 vaccination&#xD;
      alternatives requires the development of various strategies, such as stratifying the&#xD;
      population sampled by the risk of being infected or transmitting the disease, the agreement&#xD;
      for the acquisition of vaccines produced by multiple laboratories simultaneously, setting as&#xD;
      a priority first dose vaccination to a higher number of people in a shorter period of time&#xD;
      and completing the schemes already started.&#xD;
&#xD;
      The pandemic has revealed the capacity of our country to carry out research studies that&#xD;
      produce evidence to face the new challenges posed by COVID19 and, particularly,to implement&#xD;
      vaccination as one of the main tools to reduce the health impact it generates-for example,six&#xD;
      months after the start of the vaccination campaign, results demonstrate the positive impact&#xD;
      of this strategy and its effectiveness.&#xD;
&#xD;
      Models based on heterologous immunization schemes with vaccines from different platforms&#xD;
      require evaluation by means of clinical trials,in order to show whether they are not less&#xD;
      effective than homologous schemes already established. This is achieved through comparative&#xD;
      evaluation of their immunogenicity, efficacy and reactogenicity with studies considering&#xD;
      implementation possibilities, adaptiveness and response to real life situations.&#xD;
&#xD;
      Hence, the Ministry of Health propoundsthe development of a collaborative network for the&#xD;
      integration of studies on vaccination strategies against COVID-19 with the use of&#xD;
      heterologous schemes based on the evaluation of their non-inferiority, compared to homologous&#xD;
      vaccination schedulesalready implemented worldwide.&#xD;
&#xD;
      The Argentine Ministry of Health looks forward to generating solid scientific evidence that&#xD;
      supports decision-making in health policies, with broad federal participation and common&#xD;
      objectives.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2021</start_date>
  <completion_date type="Anticipated">February 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, open, multicenter, collaborative and adaptive non-inferiority trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody against Spike protein measurement by ELISA test</measure>
    <time_frame>28 days</time_frame>
    <description>To assess IgG anti Spike response (UI/ml): To assess the antibody concentration in each arm by ELISA COVIDAR IgG expressed in IU/ml. To determine whether a heterologous vaccination regimen is non-inferior to that observed with currently used homologous regimens.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events by measurement of the number of reactions after vaccination</measure>
    <time_frame>28 days</time_frame>
    <description>Adverse events events presumably attributable to vaccination and immunization (ESAVI) and adverse events of special interest (AESI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutralising Antibody against Spike protein and cellular immune response</measure>
    <time_frame>6 month</time_frame>
    <description>Neutralizing antibody titer in the serum of vaccinated individuals, using &quot;Vero&quot; cells as infection targets and cellular immune response It will be studied in heparinized blood samples using mononuclear cells isolated from the blood samples obtained. These cells will be challenged &quot;in vitro&quot; with &quot;pools&quot; of peptides from the Spike and N proteins of SARS-CoV-2, evaluating the production of the cytokines interferon-Î³ and IL-2 by T cells, by flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events by measurement of the number of reactions after vaccination</measure>
    <time_frame>6 months</time_frame>
    <description>adverse events events presumably attributable to vaccination and immunization (ESAVI) and adverse events of special interest (AESI)</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Anticipated">1760</enrollment>
  <condition>COVID-19 VACCINE</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Gam-COVID-Vac C1/ ChAdOx1 nCoV-19</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heterologous: Gam-COVID-Vac C1/ ChAdOx1 nCoV-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ChAdOx1 nCoV-19 / Gam-COVID-Vac C1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heterologous: ChAdOx1 nCoV-19 / Gam-COVID-Vac C1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gam-COVID-Vac C1/ BBIBP-CorV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heterologous: Gam-COVID-Vac C1/ BBIBP-CorV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBIBP-CorV / Gam-COVID-Vac C1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heterologous: BBIBP-CorV / Gam-COVID-Vac C1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ChAdOx1 nCoV-19 / BBIBP-CorV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heterologous: ChAdOx1 nCoV-19 / BBIBP-CorV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBIBP-CorV / ChAdOx1 nCoV-19</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heterologous: BBIBP-CorV / ChAdOx1 nCoV-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gam-COVID-Vac C1/ mRNA-1273</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heterologous: Gam-COVID-Vac C1/ mRNA-1273</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ChAdOx1 nCoV-19 / mRNA-1273</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heterologous: ChAdOx1 nCoV-19 / mRNA-1273</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBIBP-CorV / mRNA-1273</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heterologous BBIBP-CorV / mRNA-1273</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gam-COVID-Vac C1/ Gam-COVID-Vac C2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Homologous: Gam-COVID-Vac C1/ Gam-COVID-Vac C2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Homologous: ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBIBP-CorV / BBIBP-CorV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Homologous: BBIBP-CorV / BBIBP-CorV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mRNA-1273 / mRNA-1273</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Homologous: mRNA-1273 / mRNA-1273</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gam-COVID-Vac C1/ Gam-COVID-Vac C1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Homologous: Gam-COVID-Vac C1/ Gam-COVID-Vac C1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 vaccines</intervention_name>
    <description>Gam-COVID-Vac Gamaleya National Center for Epidemiology and Microbiology - Russia. Non-replicative viral vector. Multi-dose vial (5 doses in 3 mL) Single-dose vial (1 dose in 0.5 mL). Intramuscular TÂ° less than -18 Â° C&#xD;
BBIBP-CorV Beijing Institute of Biological Products - People's Republic of China. Inactivated viruses. Single-dose vials (1 dose in 0.5 mL) or multi-dose vial (2 doses per vial). Intramuscular TÂ° 2 to 8 Â° C&#xD;
ChAdOx1 nCoV-19 vaccine AZD1222 AstraZeneca-Oxford - United Kingdom. Non-replicative viral vector. Multi-dose vial (10 doses in 5 mL). Intramuscular TÂ°: 2 to 8 Â° C&#xD;
mRNA-1273 or Spikevax Moderna Switzerland GmbH and the National Institute of Allergy and Infectious Diseases (NIAID) of the United States. mRNA. Multi-dose vial (maximum 15 doses per 0.5ml vial). Intramuscular. TÂ°-15 Â° to -50 Â°</description>
    <arm_group_label>BBIBP-CorV / BBIBP-CorV</arm_group_label>
    <arm_group_label>BBIBP-CorV / ChAdOx1 nCoV-19</arm_group_label>
    <arm_group_label>BBIBP-CorV / Gam-COVID-Vac C1</arm_group_label>
    <arm_group_label>BBIBP-CorV / mRNA-1273</arm_group_label>
    <arm_group_label>ChAdOx1 nCoV-19 / BBIBP-CorV</arm_group_label>
    <arm_group_label>ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19</arm_group_label>
    <arm_group_label>ChAdOx1 nCoV-19 / Gam-COVID-Vac C1</arm_group_label>
    <arm_group_label>ChAdOx1 nCoV-19 / mRNA-1273</arm_group_label>
    <arm_group_label>Gam-COVID-Vac C1/ BBIBP-CorV</arm_group_label>
    <arm_group_label>Gam-COVID-Vac C1/ ChAdOx1 nCoV-19</arm_group_label>
    <arm_group_label>Gam-COVID-Vac C1/ Gam-COVID-Vac C1</arm_group_label>
    <arm_group_label>Gam-COVID-Vac C1/ Gam-COVID-Vac C2</arm_group_label>
    <arm_group_label>Gam-COVID-Vac C1/ mRNA-1273</arm_group_label>
    <arm_group_label>mRNA-1273 / mRNA-1273</arm_group_label>
    <other_name>SPUTNIK-V (Gam-COVID-Vac)</other_name>
    <other_name>SINOPHARM (BBIBP-CorV)</other_name>
    <other_name>AstraZeneca (ChAdOx1 nCoV-19 vaccine AZD1222)</other_name>
    <other_name>Moderna (mRNA-1273 or Spikevax)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older, vaccinated with 1 dose of Sputnik V, AstraZeneca or&#xD;
             Sinopharm vaccine up to 60 days prior to enrollment (according to the platform of the&#xD;
             vaccine received as the first dose) or not vaccinated for the mRNA-1273 / mRNA-1273&#xD;
             Arm&#xD;
&#xD;
          -  With and without identified risk factors for COVID-19&#xD;
&#xD;
          -  Signature of the informed consent&#xD;
&#xD;
          -  Remain in the jurisdiction where your study began until the end of it&#xD;
&#xD;
          -  Be able to understand and sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with immunocompromise due to underlying disease or immunosuppressive&#xD;
             treatment&#xD;
&#xD;
          -  Pregnant and breastfeeding people&#xD;
&#xD;
          -  Being registered in the National Health Surveillance System for having suffered&#xD;
             COVID-19 (symptomatic or asymptomatic) or having a positive IgG result in nucleocapsid&#xD;
             ELISA in the sample taken on &quot;DAY 0&quot; for people who had received Sputnik-V or&#xD;
             AstraZeneca as the first dose&#xD;
&#xD;
          -  Having had a severe allergic reaction (anaphylaxis) to any vaccine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Pasinovich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ministry of Public Health, Argentina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marina Pasinovich, MD</last_name>
    <phone>+5491154961973</phone>
    <email>mpasinovich@msal.gov.ar</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan Manuel Castelli, MD</last_name>
    <phone>+5492214088284</phone>
    <email>jcastelli@msal.gov.ar</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CÃ³rdoba</name>
      <address>
        <city>CÃ³rdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela BarbÃ¡s</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Provincia de Buenos Aires</name>
      <address>
        <city>La Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Pifano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Rioja</name>
      <address>
        <city>La Rioja</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Laino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Luis</name>
      <address>
        <city>San Luis</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Manuel Talia</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Public Health, Argentina</investigator_affiliation>
    <investigator_full_name>Marina Pasinovich, md</investigator_full_name>
    <investigator_title>Medical adviser on immunizations, Undersecretary of Health Strategies</investigator_title>
  </responsible_party>
  <keyword>Interchangeability</keyword>
  <keyword>Heterologous vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

